Skip to main content

Table 3 Univariate and Multivariate analysis results for PFS and OS

From: Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma

Variable

Univariate

Multivariate Model 1

Multivariate Model 2

PFS

HR (95% CI), P-value

OS

HR (95% CI), P-value

PFS

HR (95% CI), P-value

OS

HR (95% CI), P-value

PFS

HR (95% CI), P-value

OS

HR (95% CI), P-value

Sex

 Male vs Female

0.49 (0.27-0.93), p = .031

0.35 (0.17-0.71), p = .005

0.64 (0.33-1.28), p = .20

0.67 (1.09-5.46), p = .33

0.56 (0.30-1.08), p = .08

0.45 (0.22-0.93), p = .03

IMDC Criteria

 Favorable

ref

ref

ref

ref

ref

ref

 Intermediate

2.20 (0.93-6.50), p = .08

4.13 (1.23-25.62), p = .02

2.02 (0.83-6.06), p = .13

4.02 (1.16-25.33), p = .03

1.91 (0.78-5.73), p = .17

3.42 (1.00-21.48), p = 0.05

 Poor

4.46 (1.56-14.65), p = .005

10.43 (2.65-69.34), p = .0004

3.38 (1.12-11.55), p = .03

7.00 (1.68-47.83), p = .006

3.23 (1.03-11.30), p = .04

5.41 (1.20-38.24), p = .03

NLR

  ≤ 4 vs >4

0.51 (0.28-0.95), p = .034

0.31 (0.16-0.61), p = .001

0.68 (0.35-1.39), p = .28

0.41 (1.09-5.46), p = .03

NA

NA

 Continuous (per unit change in NLR

1.05 (0.99-1.10), p = .08

1.10 (1.04-1.15), p = .002

NA

NA

1.03 (0.97-1.09), p = .30

1.08 (1.01-1.14), p = .03

  1. CI, 95% confidence interval
  2. HR hazard ratio, NA not applicable, NLR neutrophil to lymphocyte ratio, OS overall survival, PFS progression-free survival
  3. Italicized p-values are less than 0.05